Article

PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibition

2024-08-27

Abstract excerpt

<title>Abstract</title> <p>The overexpression of Polo-like kinase 1 (PLK1) is linked to poor clinical outcomes in various malignancies, making it an attractive target for anticancer therapies. Although recent studies suggest PLK1's involvement in homologous recombination (HR), the impact of its overexpression on HR remains unclear. We investigated the effect of PLK1 overexpression on HR using bioinformatics and e...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f7cadd2a-f3a5-5e99-9f75-f8213e63a22d
DOI: 10.21203/rs.3.rs-4784840/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibitionDOI 10.21203/rs.3.rs-4784840/v1Read

PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibitionSemantic proximity Read

Polo-like kinase 1 (Plk1) overexpression enhances ionizing radiation-induced cancer formation in miceSemantic proximity Read

Pan-cancer Analysis of Homologous Recombination Deficiency in Cell LinesSemantic proximity Read

PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinicSemantic proximity Read

Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implicationsSemantic proximity Read

Polo-like kinase 1 mediates BRCA1 phosphorylation and recruitment at DNA double-strand breaks.Semantic proximity Read

RAD51 and PALB2 in precision oncology: Clinical implications for HRD associated breast and ovarian cancers (Review)Semantic proximity Read

Polo-like kinase inhibitors: an emerging opportunity for cancer therapeuticsSemantic proximity Read

Present and Future Perspective on PLK1 Inhibition in Cancer TreatmentSemantic proximity Read

Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell LinesSemantic proximity Read

Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51Semantic proximity Read

RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?Semantic proximity Read